Hepatitis C virus quasispecies in HIV-infected women: Role of injecting drug use and highly active antiretroviral therapy (HAART)

Laskus, Tomasz; Wilkinson, Jeffrey; Karim, Roksana; Mack, Wendy J.; Radkowski, Marek; deGiacomo, Marina; Nasseri, Jonathan; Chen, Zhi; Xu, Jiaao; Kovács, Andrea

doi:10.1002/hep.21715

Cited by 8 publications

(8 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since quasispecies complexity may also be affected by duration of infection, viral load, histology, and whether the subject is a progressor vs. non-progressor in terms of liver disease, it is likely that the variability in reporting reflects differences in comparison groups randomly selected for cross-sectional evaluation [11, 17, 18]. Variation over time was clearly demonstrated in the longitudinal cohort described by Qin et al [14].…”

Section: Discussionmentioning

confidence: 99%

Hepatitis C Virus (HCV) Quasispecies Complexity and Selection in HCV/HIV‐Coinfected Subjects Treated with Interferon‐Based Regimens

et al. 2010

View full text Add to dashboard Cite

HCV/HIV coinfection has emerged as a major cause of morbidity and mortality due to liver disease. Interferon-based therapy response rates have been disappointingly low. Baseline HCV complexity and the relationship between complexity and viral kinetic parameters has not been well described in HCV/HIV subjects. A subset of patients enrolled in ACTG 5071 underwent sampling to evaluate viral kinetics and HCV complexity changes. Early kinetic parameters, baseline complexity, and treatment outcomes, including rapid (RVR), early (EVR), and sustained (SVR) viral response were evaluated. HCV monoinfected subjects were matched to HCV/HIV coinfected subjects. RESULTS Baseline complexity was determined in 108 HCV/HIV coinfected subjects and 13 HCV controls. Quasispecies complexity was 2.24 in HCV/HIV and 1.90 in monoinfected subjects (p=0.14). Lower baseline complexity was associated with EVR (p=0.04) and approached significance for SVR. In patients who underwent viral kinetic modeling, complexity decrease was associated with RVR (p= 0.03), and was independent of the correlation between first phase viral decline efficiency and RVR. CONCLUSION Baseline HCV complexity is an independent predictor of early viral response in HCV/HIV subjects. Complexity decrease occurs by 4 weeks of interferon-based therapy and is associated with RVR. These findings may enhance predictive modeling of treatment outcomes in HCV/HIV patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Hepatitis C Virus (HCV) Quasispecies Complexity and Selection in HCV/HIV‐Coinfected Subjects Treated with Interferon‐Based Regimens

et al. 2010

View full text Add to dashboard Cite

show abstract

“…HCV genotyping was conducted on a subset of HCV viremic women using the NC TRUGENE HCV 5 NC Genotyping Kit (Bayer HealthCare LLC, Tarrytown, NY), as previously described. (24)…”

Section: Methodsmentioning

confidence: 99%

Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia

et al. 2009

Self Cite

View full text Add to dashboard Cite

M ore than 4 million women and men in the United States and 150 million people worldwide are estimated to be hepatitis C virus (HCV) seropositive. 1,2 Most of these individuals are chronically infected with the virus and are at high risk of cirrhosis, hepatocellular carcinoma, and liverrelated death. The natural history of HCV infection, however, is highly variable. Some individuals do not become HCV infected despite high levels of exposure. 3 Other individuals may clear HCV RNA following acute infection, and whereas some individuals with long-term HCV viremia remain clinically asymptomatic, others have progressive disease. 4 Indeed, marked variability in natural history is seen even among groups of individuals with single-source exposure to HCV, as occurred in a population of Irish women exposed to HCV-contaminated anti-D immune globulin. 5 Together these observations suggest that host factors, particularly host immune response, play a key role in the regulation of HCV pathogenesis.

show abstract

“…HCV viremia was determined for HCVseropositive women using either the COBAS Amplicor Monitor 2.0 or the COBAS Taqman assay (both from Roche Diagnostics), as described elsewhere [33]. HCV genotyping was conducted in a subset of HCV viremic women using the NC TRUGENE HCV 5 NC Genotyping Kit (Bayer HealthCare) [34]. HLA Genotyping.…”

Section: Study Populationmentioning

confidence: 99%

The Relation of HLA Genotype to Hepatitis C Viral Load and Markers of Liver Fibrosis in HIV-Infected and HIV-Uninfected Women

Kuniholm

Gao

Xue

et al. 2011

The Journal of Infectious Diseases

Self Cite

View full text Add to dashboard Cite

show abstract

Hepatitis C virus quasispecies in HIV-infected women: Role of injecting drug use and highly active antiretroviral therapy (HAART)

Cited by 8 publications

References 71 publications

Hepatitis C Virus (HCV) Quasispecies Complexity and Selection in HCV/HIV‐Coinfected Subjects Treated with Interferon‐Based Regimens

Hepatitis C Virus (HCV) Quasispecies Complexity and Selection in HCV/HIV‐Coinfected Subjects Treated with Interferon‐Based Regimens

Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia

The Relation of HLA Genotype to Hepatitis C Viral Load and Markers of Liver Fibrosis in HIV-Infected and HIV-Uninfected Women

Contact Info

Product

Resources

About